

Registered number: 04509293
Charity numbers: 1094231 & SC039257

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report and financial statements

For the year ended 31 March 2024

TUESDAY



ADISGE01

A05

17/12/2024

#115

COMPANIES HOUSE

The British Allergy Foundation
(A company limited by guarantee)

Contents

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 16
Independent auditors' report on the financial statements	17 - 21
Consolidated statement of financial activities	22
Consolidated balance sheet	23 - 24
Charity balance sheet	25 - 26
Consolidated statement of cash flows	27
Notes to the financial statements	28 - 54

The British Allergy Foundation
(A company limited by guarantee)

Reference and administrative details of the Charity, its Trustees and advisers
For the year ended 31 March 2024

Trustees	Mr P Frampton, Chair Mrs A Tharani, Vice Chair Mr R Daby Mr R Dudley-Southern MBE (resigned 28 September 2023) Dr B Hewitt (resigned 28 September 2023) Dr G Stiefel Dr S Kayode Ms R Oldroyd Ms L Pritchard (resigned 26 September 2024) Ms K Sykes (appointed 17 June 2023, resigned 2 April 2024) Ms E Withers Ms S Devlin (appointed 28 September 2023)
Company registered number	04509293
Charity registered numbers	1094231 and SC039257
Registered office	London House Business Centre Thames Road Crayford Dartford England DA1 4SL
Company secretary	P Turnbull
Chief executive officer	S Miles
Independent auditors	Kreston Reeves LLP Chartered Accountants Statutory Auditor 37 St Margaret's Street Canterbury Kent CT1 2TU

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report
For the year ended 31 March 2024

The Trustees present their annual report together with the audited financial statements of the Charity for the 1 April 2023 to 31 March 2024. The Annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the Annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Since the group and the Charity qualify as small under section 383 of the Companies Act 2006, the Group strategic report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

The group and the Charity also trade under the name Allergy UK.

Objectives and activities

a. Policies and objectives

The Charitable Objects for the charity are:

- 3.1 To raise public awareness around allergy and the causes of anaphylaxis.
- 3.2 To produce reliable information and education in the community for the management and prevention of all allergic reactions, including anaphylaxis.
- 3.3 To provide support in the community to all those affected by allergy, covering all manifestations of allergy to reduce risk of serious allergic reaction (anaphylaxis). This support extends to bereaved families.
- 3.4 To promote research into the cause and care for all allergic conditions, including those that cause anaphylaxis, in order to improve health and quality of life for people living with allergy and associated diseases.
- 3.5 To increase the profile of and advocacy for all allergic conditions, including the seriousness of anaphylaxis, providing advice and representation to government, industry, and other organisations, and being a conduit for information and research for a range of expert and patient stakeholders.
- 3.6 To campaign for policy and legislative changes to improve the lives of all people living with allergy, including those who live with the risk of anaphylaxis.

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

Achievements and performance

a. Main achievements of the Charity

In 2023/24 we continued to work towards our strategic objectives as set out in our Strategy for Change 2020-2025 plans.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2024

Achievements and performance (continued)

Research – Understanding Allergy

Patient Charter for People Living with Allergic Disease

Research is used to inform the services we provide and public affairs campaigns. We lobby on behalf of the allergic community, and the strategic approach of the charity. Our real-world evidence survey and focus groups in 2021 led to a collaboration between patients, carers, clinicians and Allergy UK and the development of a Patient Charter for People Living with Allergic Disease. The Charter's key focuses are:

- A right to a quality standard of care: for everyone living with allergy throughout the UK
- A right to accurate information and education: Empowerment of patients with allergic conditions to understand and manage their condition with support from informed healthcare professionals
- A right to equality in society: Promotion of a better awareness and understanding of allergy so that people with allergic conditions are not discriminated against in any aspect of their daily lives.

Since the inception of the charter, our campaign has concentrated on advocating for the inclusion of specialist allergy nurses and dietitians within every Integrated Care Board (ICB). ICBs are not tasked with commissioning allergy services at a local level and do not encompass specialist services. In March 2023, Allergy UK submitted a Freedom of Information request to all 42 ICBs. The findings from this request were regrettably unsurprising, indicating that allergy services do not adequately address the genuine needs of the population. Out of 42 NHS England ICBs approached, 32 provided responses, while the remaining 10 did not reply. Among the 32 ICBs that responded, only 3 (representing 7% of all ICBs) possessed data regarding the number of patients within their area who had been clinically diagnosed and coded with an allergy. Currently, there are only 8,539 patients whose conditions are documented at the ICB level during the specified timeframe. The research has been instrumental in shaping meetings and Westminster Briefings with the Government. We continue our efforts to raise awareness about the critical nature of allergies and the necessity of improved allergy services.

In the latter end of 2023, Allergy UK commissioned a food allergy community survey for our food allergy phase of Its Time campaign, Ingredients Matter. Although Allergy UK have a significant amount of anecdotal evidence about the challenges of living with a food allergy from lack of transparent labelling, refusal of service at restaurants and heightened anxiety for those affected. We were missing robust, qualitative data that can be used more effectively to utilise and inform our planned initiatives over the coming years. This survey looked to understand the daily implications and restrictions faced by the food-allergic community to keep themselves safe. We are currently reviewing the data to understand how best to use it to inform our community and the work we do.

Empowering – supporting and informing through our Helpline and resources

There has been a notable rise in the demand for support services for individuals facing mental health challenges, including anxiety and depression. Our advisers offer immediate assistance and appropriate referrals to either our internal specialist clinical team or external services as necessary. In the fiscal year 2023/24, we assisted 7,000 individuals through our helpline, marking a 53% increase compared to 2022/23. Additionally, our Allergy Translation Card Service offers both plastic and PDF cards in 35 languages for those needing to communicate their allergies in a language other than English. During 2023/24, we processed 2,095 translation cards. In March of this year, we launched an enhanced online ordering system, allowing customers to request their cards at their convenience. Preliminary feedback indicates that this new method is well-received, with a significant number of orders being placed outside of regular business hours. We anticipate providing more comprehensive insights next year after a full year of service operation. This development is beneficial for both consumers and the charity, as it enhances service accessibility and contributes to increased revenue for the organisation.

We extend our gratitude to our Health Advisory team for their dedication in providing expert clinical support for calls received through our helpline.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2024

Achievements and performance (continued)

Eczema Clinic

Allergy UK boasts an in-house clinical team dedicated to providing expert support for allergy-related issues. In our annual report from the previous year, we recognised the necessity of establishing an Eczema Service. We are pleased to announce that a Nurse Led Eczema Clinic began its testing phase in September 2023, operating one day each week. From September to March, the clinic assisted 16 children and their families dealing with persistent and challenging eczema. The service is conducted through personalised telephone consultations, offering guidance and support to help parents better comprehend and manage their child's atopic dermatitis. Following a review of the service's impact, we have decided to continue the clinic, with the aim of securing funding through grants or sponsorship.

Dietitian Service

The service has been operational since 2015, assisting more than 1,700 children throughout this time, with 286 children receiving support in the 2023/24 period. It offers assistance to parents and caregivers of children with suspected food allergies, providing professional dietetic intervention while they await an appointment with the NHS. We aspire for this service to remain sustainable through ongoing grants and sponsorship, as feedback from parents consistently highlights the necessity of such support and the significant positive effects it has on both them and their children.

We get frequent positive feedback from parents using the service. This is one example. *My free phone call with a dietitian for my baby was extremely helpful! I've been in contact with my GP around 8 times, and they've not helped, so getting advice from someone else was nice! They (helpline adviser) helped put my mind at ease with tips for how to help my allergy baby wean and what new foods to try them with and when. My GP also received a letter which hopefully will help to speed up my referral for allergy tests. I'd recommend the service to anyone who struggles with food allergies and has not gotten help anywhere else. Thank you!*

Youth engagement

Over the past year, the youth engagement program has experienced significant growth and development. The Youth Engagement Group has convened on 12 occasions, in addition to 10 steering committee meetings and 10 discussions between the Chair, a young member of the group, and the lead representative from Allergy UK. The typical attendance of young participants fluctuates between 9 and 15 individuals. The youth group delved into various allergy-related topics, receiving guidance from our in-house clinical team. In the upcoming year, we plan to broaden our youth groups to include a younger demographic. Regrettably, funding for a youth engagement officer has concluded. We are actively pursuing grants to secure additional funding. In the interim, the engagement program is being managed by another team member with expertise in youth engagement.

Allergy UK has engaged in an exciting initiative in collaboration with the Girl Guides London and South East region (LASER) to develop an allergy awareness badge. We are delighted to announce that the Allergy Aware badge was officially launched in April 2024. This badge aims to empower the younger generation to become more knowledgeable about allergies and to assist their peers who may be affected. The partnership with the Girl Guides adds significant value, as it includes a commitment to fundraising efforts for Allergy UK. Should the badge prove successful in its inaugural year, we aspire to extend this initiative to additional regions throughout the UK.

Educating – improving awareness, knowledge, and skills in allergy

Our educational resources support patients, carers, and non-specialist healthcare professionals in developing knowledge of allergic disease and in 2023/24 we developed many excellent additional resources to provide advice and information for people living with allergy.

We launched a skin focused phase of our campaign called "It's Time" using digital ads, social media and case studies. The campaign performed very well reaching three times as many users compared to previous campaigns.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2024

Achievements and performance (continued)

We served as a collaborative partner for National Eczema Week, actively disseminating information via our social media posts. Our specialist allergy nurse provided valuable insights through a Facebook post featuring three essential tips for individuals caring for atopic eczema skin. Additionally, a live Q&A session was conducted to commemorate World Eczema Day.

Allergy UK successfully conducted two Allergy Awareness weeks. In April, we introduced a new Parent Pathways Hub on our website, which achieved the highest level of positive engagement compared to any other resource launched on social media. Our second awareness week in October 2023 concentrated on indoor allergies, utilising a variety of social media posts to provide valuable information on this topic.

As 2023 drew to a close, we initiated the #IngredientsMatter campaign, a creative initiative within the food segment of the It's Time Campaign. This social media campaign, characterized by organic outreach, aimed to strengthen connections with the food allergic community. The reach of #IngredientsMatter surpassed that of the previous Food Campaign, despite both campaigns being active on social channels for the same duration as the prior year. This initiative has also positively impacted our Instagram follower count, reflecting a year-on-year growth of 25%.

We have created various resources aimed at individuals affected by allergies. These include a patient experience narrative regarding immunotherapy, a video showcasing the experiences of a child with House Dust Mite Allergy from both the child's and the parent's viewpoints, as well as an informational leaflet on cow's milk allergy. Additionally, our website has been enhanced to feature a dedicated section for parents of young individuals, providing them with access to trustworthy resources to assist in their allergy management.

In recent months, Allergy UK has engaged in a partnership with the Helen Blythe Foundation to establish Schools Allergy Education Standards aimed at enhancing awareness and care for children with allergies in educational settings. This initiative stems from a Freedom of Information request directed at schools in England, inquiring about their management of allergies. The findings from the Ready to React Report indicated significant variability in training, with over 40% of teachers expressing that they did not feel adequately prepared to handle a child's allergy. In light of these results, Allergy UK, in collaboration with other stakeholders, has been working on developing Allergy Standards for schools. The Department for Education has communicated its support for this initiative and has expressed a willingness to collaborate with partners on the subsequent steps. This effort will extend into the 2024/25 period.

We have continued our efforts to educate healthcare professionals (HCPs) through our Masterclasses. In 2023, we conducted three Masterclasses focused on food allergy, eczema, and the weaning process related to food allergies. These Masterclasses have seen strong attendance. The online training attracted a total of 987 participants on the day of the event, with an additional 611 accessing the training after the live session. Over 97% of participants rated the training as either excellent or good. Furthermore, we have supplied HCPs with valuable resources, including an eczema e-booklet designed to assist in accurate diagnosis, as well as a podcast that delves into Paediatric Asthma and the application of corticosteroids.

In April 2023 we refreshed our HCP's publication. The new publication is a 'bite-size' approach to information.

We had anticipated the launch of our own catering program in 2023. This program is designed to address the identified gaps and assist catering staff in enhancing their confidence when serving individuals with allergies. However, due to limitations in staff resources, the launch has been postponed. We expect to introduce the program in the upcoming months.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2024

Achievements and performance (continued)

Influencing – connecting with key stakeholders

The Patient Charter Digital Hub was inaugurated in 2023, featuring the establishment of a pledge wall and the creation of a government petition aimed at prompting governmental action. This initiative was bolstered by a public relations campaign that garnered support from an Allergy UK advocate and facilitated media coverage across television and radio platforms. During the 2023-2024 period, we actively engaged with parliamentarians to enhance awareness regarding allergies and to persist in our calls to action stemming from the Patient Charter introduced the previous year. In May 2023, we participated in a Westminster Hall debate concerning a national lead for allergy and food labeling on menus, while also striving to encourage more Members of Parliament and Peers to assume the role of Allergy Champions, of which we currently have twelve. In March 2024, we organized a drop-in event at Westminster for MPs and Peers to unveil our election manifesto: This manifesto serves as the cornerstone for our calls to action for the 2024-2025 period, complementing our ongoing campaign message, "It's time to take allergy seriously," by engaging with key influencers and stakeholders to raise awareness about living with a chronic condition. The political landscape for 2025-2026 will present new challenges and opportunities with the advent of a new government.

Allergy UK plays a pivotal role as a core member of the National Allergy Strategy Group (NASG), for which we also serve as the secretariat. Our primary objective within the NASG is to formulate a National Allergy Strategy, and we are proud to actively contribute to this initiative, which is set to be a live document by autumn 2025. Over the past year, the NASG has formed its Expert Advisory Group to assist in the development of the National Allergy Strategy and to guide policy formulation.

The All-Party Parliamentary Group (APPG) convened for its Annual General Meeting, during which its members demonstrated their invaluable support for our efforts to enhance awareness of allergies. We extend our gratitude to all APPG members and to the Chair, John Cruddus, for his steadfast commitment to our initiatives. As the Chair has now retired and stepped down, our focus for 2024/25 will be to seek a new Chair and additional members for the APPG, ensuring that we maintain a network of peers and parliamentarians for the future.

Allergy UK also plays a key influencing role at a UK level with involvement in:

- the National Allergy Strategy Group,
- the steering group of the Children and Young People's Allergy Network in Scotland (CYANS)
- the Patient and Public Voice partner for NHS England's Specialised Commissioning Clinical Reference Group for Immunology and Allergy Services
- represents patient perspectives when asked by the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute of Clinical Excellence (NICE)
- a member of the Royal College of Physicians' Improving Quality in Allergy Services (IQAS) accreditation steering group
- is a patient representative in many of the British Society for Allergy and Clinical Immunology (BSACI) activities
- has regular meetings with the Food Standards Agency (FSA) and is a contact for the Food Standards Scotland (FSS)

Allergy UK exerts its influence at both European and global levels through partnerships with various peer organisations. We work in conjunction with the European Federation of Allergy and Airways Diseases, the European Academy of Clinical Immunology, and the Global Allergy and Asthma Patient Platform. During the 2023/24 period, our participation has encompassed attending steering groups focused on skin and food allergies, developing resources applicable across Europe, and representing the UK to promote best practice.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2024

Achievements and performance (continued)

b. Fundraising activities and income generation

Allergy UK is registered with and has paid the Levy required by the Fundraising Regulator. The Charity is a member of the Institute of Fundraising and complies with all required regulations, including ensuring all procedures comply with General Data Protection Regulations, thereby protecting the data of all who contact the Charity. We are pleased to advise that we have not received any complaints relating to fundraising during this year.

A primary objective of our organisation is to enhance our capacity for income generation to ensure the long-term sustainability of the Charity. This will necessitate the development of a variety of income sources, including unrestricted funds and grants that will support our essential services. Below, we outline our existing income streams. The current environment for charities striving to meet their income goals remains challenging, as numerous Trusts and foundations are constrained in their ability to provide funding, particularly in light of the increasing number of charities seeking financial support. However, we have received indications that 2024 may herald a shift, with a rise in available grant opportunities.

- Corporate Partner and grants
- Community fundraising and individual contributions
- Trusts and grants
- Income generated through the charity's trading subsidiary, Allergy Research Limited

We would like to express our thanks to all the companies that continued to support Allergy UK to meet its service delivery objectives. This support is essential for the sustainability of the charity be it through corporate sponsorships through our trading subsidiary or our corporate grants.

In 2023/24 we had 13 establish corporate partners which has supported the delivery of key services, such as our Dietitian Service, Masterclasses, an array of resources and national and world campaigns such as World Eczema day and world eczema week. For this, we wish to thank Abbvie, Polti, Nutricia, Global Skin, Haymax, Novartis, Olsson, Pfizer, Sanofi, Viatris, +Ecohydra, Thomas and Leo Pharma.

Community Fundraising

The Hope Hoot is a musical event/hootenanny that was led by John, Tamsin, and Jack Schwab held on behalf of Allergy UK and another allergy charity. The primary purpose of the event was to raise awareness about allergies and the much-needed funds for charity. The event was a success, and we are scheduled to repeat the event in 2025.

Our Christmas campaign for 2023, My Life, your Hands focused on a young person who almost passed away after being served the wrong dish whilst dining out with friends. The key objective of the campaign was to raise awareness of the seriousness of allergy, highlighting the need for changes in training and education for the hospitality sector. The My Life, Your Hands Campaign was also the launch pad for sharing the great news that Allergy UK are working in partnership with Girlguiding. The project used the campaign as launch pad to promote the introduction of an allergy badge from April with 44,000 Leaders, Guides, Rangers, Brownies and Rainbows from London and Southern England in the coming year. We are working towards a national roll out program in 2025. As well as raising awareness among children, young people and their families the collaboration with the girl guides will help raise funds to help Allergy UK meet its objectives. For our My Life, Your Hands Christmas event we raised income by 52% compared to the previous year.

Event attendance at the venue went up by 63% and online attendance by 233%. We were also fortunate to receive £5780 worth of gift-in kind and pro-bono support. We would like to thank Tesco, Asda, Genius Foods, B&Q, and our celebrities that supported the event.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2024

Achievements and performance (continued)

London Knightz continues to offer their ongoing support to the cause and have held a sponsored walk in memory of Ruben, in which Allergy UK received £1,598. Allergy UK would like to extend our most sincere and heartfelt thanks to the Bousquet family, The London Knightz and all those who have so generously supported us over the past year.

Allergy UK is extremely grateful to all of our supporters and those who have donated through fundraising, donating to appeals, legacies and other ways, as despite the continued difficulties from the economic impact our supporters continue to give. We achieved a 27% increase compared to the previous year. We are finding that our donations have increasingly become 'one-off' donations rather than regular giving. We would assume that people are still not able to give regularly but will give when they can financially afford to.

Trust Fundraising

The year 2023 has proven to be a difficult period for trust income, and we were unable to achieve our targets. Nevertheless, our bid writer has persistently cultivated essential relationships with funders and has enhanced the quality of our bid submissions, leading to some emerging successes. We have observed that the timeline for grant decisions is longer than anticipated, but we remain optimistic for improvements in 2024/25.

We extend our gratitude to Global Skin for their contribution of \$2,407 CAD, Nutricia for £1,008, Kiln Family Trust for £500, Michael Cornish Charitable Trust for £1,000, Coop for £1,598, Novartis for £23,177, Garfield Weston £12,500 and AbbVie for £408 for their ongoing support through grants that facilitate our work.

Endorsements and Licensing

Our trading subsidiary Allergy Research Limited provides endorsements for products which may provide support for the symptoms experienced by people living with allergy. The company donates all profits to Allergy UK each year enabling the charity to utilize these unrestricted funds for operational and other costs. The income raised from endorsements and licensing remains consistent and is the core income for the charity. However this still is of the backdrop of a challenging economic climate. ARL have experienced a slower response time for them to commit to one of our endorsement programmes. However interest has remained high as such, as a key area to generate income for the charity additional resource has been placed within the team to support the opportunities to grow the income in this area.

All donated income from the trading subsidiary directly finances the charity's expenditure on operational activities and staffing resources. Operational expenditure provides a helpline; the funding of a communications team to promote awareness of allergic diseases; the employment of three allergy nurses and a dietitian to support the helpline and provide subject matter expertise on allergy and immunology; a team supporting the trading activities and involvement with other organisations with the similar focus on areas of allergic disease. All surpluses will be used to finance future charitable expenditure, either for ongoing activities, or one-off projects.

The trading subsidiary provides the Charity's principal funding source and continued to perform well despite the difficult global economic conditions. Both its major activities (operation of endorsement programmes and working with corporate partners) exceeded expectations for the year, the budget for which had remained conservative when considering the economic forecasts. Our trading subsidiary activities are all aimed to be of benefit towards achieving the Charity's aims to provide support for those living with allergy and raise awareness of allergic disease.

Cash flow has been closely monitored throughout the year and all outflows are planned and well within the Charity's resources. We have recently reviewed where we hold our reserves to ensure they are accessible if required and gain the best return rate.

The activities carried out by the Charity's subsidiary, Allergy Research Limited, require higher costs compared to a charity which only seeks public donations. The endorsement scheme independently tests applicants' products using specialist laboratories at commensurate fees. Allergy Research Limited activities involve delivering projects, which are supported by sponsorship from our corporate partners. These projects are aimed at increasing public and healthcare professional knowledge and awareness of allergy issues.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2024

Achievements and performance (continued)

The endorsement schemes and projects incur costs to enable the achievement of outcomes and many of them are now delivered through digital solutions for which the Charity utilises third party providers. These costs are covered using donated contributions from our corporate partners and any surplus funds designated for this purpose. The majority of the Charity's income is generated, via the subsidiary, by these two means.

Financial review

a. Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the accounting policies.

b. Reserves policy

The Board of Trustees reviewed the reserves policy in accordance with the charity's strategic planning, operational decisions, budgeting and risk management processes. At every Board meeting, the Trustees can see the movement in reserves and, therefore, are aware of the level of reserves held by the charity. In addition, the reserves position is usually formally reviewed twice a year in February and September.

Financial risk management for the group includes ensuring that there is sufficient contingency reserve to enable the group to respond to an unforeseen event or emergency. The Trustees provide the CEO with the authority to make financial decisions relating to operational need, providing there are three to four months contingency reserves available. This is revisited every 6 months to ensure good financial practice. It is Allergy UK's policy that any financial decision that would result in reducing the contingency reserves to under four months of the charity's operational costs would have to be escalated to the Board of Trustees for a decision.

The charity receives a steady income stream from its trading subsidiary, and it is considered highly unlikely that this would cease immediately. It is assumed that, to set the reserves level, income must be set at a level equal to or exceeds expenses. There could, however, be a steady or sudden reduction in income arising from events outside of Allergy UK's control and sufficient reserves should therefore be held to cover a stressed drop in income over a period of six months. This would give management time to reduce headcount/costs to match the lower levels of income.

The average monthly income for the group in 2023/24 was £116,692 and is currently £94,548 (Sept 2024) excluding inter group charges. The average operational costs (BAF overheads) were £101,188 and are currently £88,812 (Sept 2024). The balance on the contingency reserve at 31 March 2024 was £466,220 so currently we are comfortably within those margins.

The contingency reserve must be held on deposit accounts at a mix of terms and maturity dates, but not exceeding 12 months, to enable the funds to be accessed when required.

The Trustees expect management to maintain a reserve cushion at least equal to the three-month minimum and must be notified immediately when this drops below the four months provision level.

The designated reserves on the balance sheet continue to differentiate free funds from those invested in fixed assets or committed to other specific projects. However, designated reserves represent free reserves allocated for a specific use by the Board and can be reallocated at their discretion. This differentiates them from restricted reserves that have been received for a specific purpose and can only be used to deliver that objective.

Over the coming year management and the board will be revisiting our Reserves Policy and ensuring that we have appropriately considered any ongoing/upcoming projects and our working capital requirements to provide a more detailed approach to defining our Reserves Policy and minimum level of general funds. This will provide us with a clear basis to communicate how we plan to utilise any surplus or to make up any shortfall.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2024

c. Financial statements

The financial statements for the year end for 2023/24 show an income of £1,400,303 and expenditure of £1,404,697, decreasing reserves by £4,394.

The charity's income was severely below budget mainly due to recorded Grants being below Budget by £173,343. This was offset to some degree by better-than-expected settlement monies from our former Planwell House landlord with a total of £113,688 being received.

On a positive note, costs were well controlled during the year and overheads were £130,632 less than budgeted. Salary savings of £84,836, mainly attributable to vacant posts, were the largest element of this.

The trading subsidiary, Allergy Research Limited (ARL), profit at year end was £654,625. Both Testing and Corporate Partner income were seriously below Budget. This was mainly offset by above than expected renewal income.

d. Principal risks and uncertainties

A strategic risk register is consistently updated and presented at each board meeting of the charity and its trading subsidiary, with more frequent updates as necessary, detailing planned mitigation strategies and the status of all identified risks. It has been recognised that Allergy UK has the potential to enhance its risk recording practices. Therefore, in 2024, we will evaluate the existing recording methods and implement improvements after the assessment.

Economic climate and cost of living

The economic crisis persisted into 2023/24, impacting all sectors, including charitable organisations. Reports indicate that many funders issued fewer funds in 2023 compared to previous years, despite an increase in the number of charities seeking financial support. According to information from the Institute of Fundraising and various funders, this situation is expected to improve by late 2024. Despite the challenging economic environment, our regular donations have remained stable, along with other fundraising revenues meeting budgetary expectations.

Amidst income challenges, 2023/24 also witnessed a continued rise in service costs, increased salaries aligned with market benchmarks, and expenses associated with the office relocation.

In the 2022/23 period, we noted a shift in the nature of contracts secured by ARL, a trend that has persisted into 2023. Our ARL clients have shown a reluctance to explore new products, preferring to maintain their existing offerings. Additionally, many of our corporate partners underwent significant organisational changes throughout 2023, which adversely affected Allergy UK's ability to secure substantial corporate funding. However, early 2024 has brought a positive shift, with corporations beginning to establish favorable relationships and demonstrating a willingness to support Allergy UK's services.

Finance and Audit

In 2022, we highlighted the difficulty in locating a suitable Finance Business Manager with the necessary qualifications following the departure of the previous individual. The recruitment process extended nearly a year, during which we engaged an external accountancy firm to oversee the financial accounts. Consequently, a significant portion of the financial responsibilities was assigned to the CEO and Operations Director. Upon successfully filling the position in November 2022, 2023 was designated for the integration of the newly established Xero accounting system and for the new Finance Business Manager to familiarise themselves with the financial framework of Allergy UK. Throughout the year, we also conducted a review and update of the financial procedures, developed a staff finance procedure, and provided training to the staff. The accountancy firm Oculus continues to assist Allergy UK with payroll processing. Additionally, we have retained Kreston Reeves as our auditors for another year, as approved by the Board of Trustees.

Recruitment Challenges

The post-pandemic era has presented significant challenges. During the COVID-19 crisis, the team experienced reductions due to redundancies and some staff members opting not to return, leading to recruitment difficulties as we aim to rebuild the team in 2023. Throughout this year, we have seen some employees depart, and the search for suitable replacements has proven to be arduous. In July 2023, the CEO resigned, and it was not until March 2024 that the position was permanently filled, during which time an interim appointment was made. Several positions remain unfilled, and work has been adjusted accordingly. This situation arises from the cessation of funding with no alternative income sources for certain roles, as well as structural changes that have rendered some positions unnecessary.

The transition back to the office following COVID-19 has been relatively seamless. However, our current model, which entails three days in the office and two days of remote work, poses challenges in attracting new staff. Many candidates express a preference for a greater number of remote workdays. This is an aspect that the charity continually evaluates. Presently, Allergy UK has determined that the existing hybrid model is effective for the organisation, but this will be reassessed annually as we monitor trends in the UK and identify prevailing practices.

To foster a collaborative team environment, we organised a staff day in December and introduced Staff Awards for the first time. The feedback from employees was overwhelmingly positive, highlighting the appreciation for recognition. We plan to hold another staff day in the summer of 2024. Additionally, we have engaged with staff to identify potential benefits they would find valuable. Numerous suggestions were made, many of which have been approved, including Life Assurance coverage, access to a benefits platform, regular team gatherings, and the continuation of hybrid working arrangements. We will persist in reaching out to staff, encouraging further ideas to enhance employee welfare and work-life balance.

Lease and Office Move

In July 2023, Allergy UK transitioned to a new location, a decision prompted not by preference but by our landlord's request for us to relinquish our lease over five years ahead of schedule, due to their intention to repurpose the building. Such a significant relocation can often lead to disruptions; however, I am pleased to report that the process was executed smoothly, thanks to the efforts of the Allergy UK team. They have adapted well to the new environment, which adequately fulfills all necessary requirements. Furthermore, we receive excellent support from the landlord, who ensures that the building remains suitable for our needs and promptly addresses any inquiries we may have.

Succession Planning for a new CEO

In 2022, our CEO informed the Trustees and Directors of their intention to resign after eight years in the position, citing health and personal reasons. They provided an extended notice period, with a departure date set for 31st July, 2023, allowing the charity and its trading subsidiary ample time to formulate a succession plan. The Operations Director assumed the role of interim CEO during the recruitment process for a new CEO, which began in the first quarter of the financial year and initially yielded a successful appointment. Regrettably, the selected candidate withdrew in September 2023, leading to a new recruitment effort that commenced in October 2023 but did not succeed. At this juncture, the Interim CEO chose to apply for the permanent position and was appointed in March 2024. Since taking on this role, the CEO has concentrated on advancing the organisational objectives and crafting the strategic plan for 2025-2030, ensuring optimal support and services for the allergic community in the future.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2024

Sustained income generation

The primary financial risks encountered by the Charity are associated with the performance of its trading subsidiary, which is essential for generating the anticipated profit levels. The Charity heavily depends on donations from this subsidiary to fund a significant portion of its charitable expenses. Additionally, there are risks related to diminished donations, challenges in obtaining grant funding, and a potential decline in engagement from corporate partners with our initiatives.

Our forecasts for the next three to five years underscore the necessity for enhanced income streams to ensure the Charity's stability and to prevent the need for significant staff restructuring. In 2023, our trading subsidiary formulated a business execution plan aimed at income generation. To facilitate this plan, additional resources within ARL were deemed necessary, and this position was successfully filled at the start of the 2024/25 financial year. It is anticipated that the new staff will help generate numerous leads, expand our customer base, and ultimately increase revenue. Nevertheless, the ongoing difficulties in securing income through trusts and grants, coupled with the need for stringent monitoring of the Charity's expenditures, remain pressing concerns.

Financial projections indicate that the Charity should be able to cover its operating costs in the coming years; however, this area continues to pose challenges, particularly if the Charity aims to fulfill its future strategic goals. Investing in the diversification of the Charity's income sources is expected to mitigate the risks associated with any single stream being negatively impacted. However, this effort occurs within a context of resource constraints faced by many organisations in the third sector.

These financial risks are monitored closely by the Chief Executive and Finance Business Manager on a daily basis, and the Board are provided with regular financial updates and forecasts to enable them to assess the Charity's financial position.

This is a proper reflection of the use of designated funds and the payment of liabilities included on the balance sheet at 31 March 2024. The cash resources have been placed on deposits ranging from instant access to 12-months fixed-term, in a manner that provides for the funds to be available should they be required. In this way we seek to maximise the interest earned from prudent investments while maintaining the accessibility of these resources.

Structure, governance and management

a. Constitution

The organisation is a charitable company limited by guarantee, incorporated in August 2002 having been first registered as an unincorporated charity in 1991. The company was established under a Memorandum of Association which states the objects and powers of the charitable company and is governed under its Articles of Association. In addition to the Memorandum and Articles of Association the charity also operates under the Code of Good Governance approved by the National Council of Voluntary Organisations and the Charity Commission.

b. Methods of appointment or election of Trustees

A maximum of 12 Trustees can be appointed and there are currently 9 on the Board as of March 2024. The Trustees meet at least four times a year at board meetings, with an Annual General Meeting was held in September.

The Board of Trustees is responsible for the strategic direction of the Charity and its policy. The Chief Executive (CEO), and appropriate members of the Executive team, attend the Board meetings as required but have no voting rights.

The directors of the company are also the charity Trustees for the purposes of charity law and serve for a period of three years but may be re-elected for further periods of three years, up to a 10-year period. Our Trustee Katherine Sykes stepped down in March after a short term on the Board. Roy Dudley- Southern MBE, Brian Hewitt also stepped down as their term came to an end. The Board would like to say a huge thank- you to Katherine, Roy and Brian for their commitment and contribution over this term.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2024

Structure, governance and management (continued)

The Trustees have the power to appoint any person to be a Trustee who may have a required skillset or expertise. By the nature of the work that the charity carries out, medical and business knowledge is required on the Board of Trustees, and this is well represented on the present board

Trustees regularly review the skills within the Board against a desired list of skills, and this informs recruitment of Trustees. In a recent skills check the Board have recognised that the board would benefit from additional trustees with skills in fundraising and marketing. In the coming 12 months, this will be addressed to try and secure this particular skill set. The skills and expertise of the Trustees are used appropriately to steer the charity and to support the CEO as and when required. We have been privileged to have such new expertise on the Board of Trustees, and during 2023/24 recruitment is continuing.

c. Organisational structure and decision-making policies

Allergy UK is led by a Chief Executive Officer (CEO) who collaborates with the Board to achieve the organisation's strategic goals. The CEO possesses delegated authority over the Charity's resources and oversees its daily operations.

Following Carla Jones's resignation as CEO on 31st July, 2023, Simone Miles assumed the role of Interim CEO, having previously served as the Operations Director at Allergy UK. This interim position was maintained until the recruitment process for a new CEO was finalised. During this period, the Head of Fundraising took on the responsibilities of Interim Operations Director. In March 2024, Simone Miles was officially appointed as CEO, and Jon Rodriguez was named Operations Director in May 2024.

The Executive team, which comprises the Operations Director, Finance Business Manager, and Head of Clinical, offers specialised knowledge and assists the CEO in managing the charity's operations and its trading subsidiary. Since the Senior HR Officer's departure in August 2023, the Operations Director has also taken on responsibilities for HR and Facilities, opting not to fill this position but instead to manage these functions through outsourced services. The Executive team supervises the Operational Management team, which is tasked with executing service area activities aimed at fulfilling our objectives in clinical services, communications, endorsements, fundraising, and helpline support. Additionally, team members with expertise in project and data management aid the charity in coordinating projects funded by grants and sponsorships, as well as in developing our customer relationship management system and data management strategies.

d. Policies adopted for the induction and training of Trustees

New Trustees are provided with a recruitment pack which provides detailed information on the work of the Charity, the Memorandum and Articles of Association, the Charity Good Governance Code, which sets the principles and recommended practice for good governance, trustee job description and responsibilities and the last published accounts. An induction period is arranged for new Trustees to familiarise themselves with the charity's work. They are welcome to our offices as well as on-line engagement with the team. In 2023 all trustees were invited to attend the December staff day and staff awards and the staff day in the summer of 2024. In the next 12 months we will be reviewing the Trustee induction to ensure that it meets the requirements to on-board trustees effectively.

e. Pay policy for key management personnel

The Trustees consider the Board of Trustees and the Chief Executive as key management personnel of the Charity. No remuneration was paid to the Trustees in the year except for relevant expenses.

The pay of the Charity's Chief Executive is reviewed annually by the Board of Trustees and benchmarked with charities of similar size. The Board acknowledged that the Chief Executive's pay in line with benchmark position and awarded an increase to reflect this.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2024

Structure, governance and management (continued)

f. Salary remuneration for staff

All salaries are benchmarked and reviewed each year. In May 2023 the Trustees received a proposal from the Executive team which was discussed and in June 2023 approved a pay increase of 3% for employees, back dated to April 1st 2023, with some adjustments depending on length of service under one year. There were also two posts which received increased salaries due to benchmarking and performance.

g. Allergy UK staff training

All staff complete mandatory training for compliance with safeguarding and health and safety legislation. In addition, our clinical team deliver in-house training for all staff on allergic disease, to take all staff through a journey of understanding on the breadth of allergy, what it is and how the immune system's immunoglobulin E is influencing allergic reactions. This in-house training covers atopic eczema, allergic rhinitis, allergic asthma, food allergy, eye allergy and anaphylaxis and other additional education identified.

In 2023 all staff completed the mandatory on-line training, which included Health and Safety, Fire Safety Awareness, Equality, Diversity & Inclusion and Cyber-Security. The Leadership Team also complete Management training. Individual staff also have an annual appraisal, with regular one-to-ones with their line managers and identified training needs included in personal development plans to ensure the charity and its trading subsidiary are supported by skilled and experienced team members.

h. Health Advisory Board

Allergy UK has established a longstanding Health Advisory Board comprising over 20 members. In March 2024, it was mutually agreed upon by the Board and the CEO that a review of the Board is necessary. This process is currently in progress, overseen by a designated Trustee, the CEO, the head of Clinical, and the current Chair, Professor Adam Fox. The review in 2024 will assess the existing members of the Board, aiming to update its Terms of Reference and identify any knowledge gaps that may necessitate recruitment. It is important to note that the Board will not receive any financial remuneration. I would like to express my gratitude to all members of the Health Advisory Board for their invaluable support to Allergy UK.

i. President and Vice-President

Professor P. Howarth, our esteemed President, is a founding member of our Charity. He served as a Professor of Allergy and Respiratory Medicine and held the position of Honorary Consultant Physician in Medicine at the University of Southampton. Renowned internationally, he has dedicated his career to advocating for the allergic community, including his previous roles as a Trustee and Ambassador for Allergy UK. We extend our heartfelt gratitude for his unwavering support over the past thirty years. Professor Howarth has now stepped down from his position, and Allergy UK is actively seeking a new president.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2024

Plans for future periods

In 2024/25 we will continue to adhere to the organisations current objectives but also plan for our new 2025-2030 strategy. Our focus for the next 12 months include:

- Development of the 2025-2030 Strategy
- Continued monitoring of the economic situation and the effect this has on the Charity's income streams and other activities
- Empowerment of the voice of the allergic community through advocacy and our 'It's time to take allergy seriously' campaign and other public relations activities across the UK
- Expanding our supporter bases and ensuring we promote programmes that have a significant impact on the quality of life of the allergic community
- Broadening the work that we are doing with UK companies, as we continue to diversify our income generation activities through fundraising and our trading subsidiary activities
- Exploring new and innovative revenue-generating opportunities
- Continue to develop our youth engagement programmes

Statement of Trustees' responsibilities

The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and the Charity and of their incoming resources and application of resources, including their income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

- so far as that Trustee is aware, there is no relevant audit information of which the charitable group's auditors are unaware, and
- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable group's auditors are aware of that information.


The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2024

Auditors

The auditors, Kreston Reeves LLP, have indicated their willingness to continue in office. The designated Trustees will propose a motion reappointing the auditors at a meeting of the Trustees.

Approved by order of the members of the board of Trustees and signed on their behalf by:



Mr P Frampton
Chair

Date: 21/11/2024

The British Allergy Foundation
(A company limited by guarantee)

Independent auditors' report to the Members of The British Allergy Foundation

Opinion

We have audited the financial statements of The British Allergy Foundation (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 March 2024 which comprise the Consolidated statement of financial activities, the Consolidated balance sheet, the Charity balance sheet, the Consolidated statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 March 2024 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

The British Allergy Foundation
(A company limited by guarantee)

Independent auditors' report to the Members of The British Allergy Foundation (continued)

Other information

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' report for the financial year for which the financial statements are prepared is consistent with the financial statements.
- the Trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a Strategic report.

Responsibilities of trustees

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Independent auditors' report to the Members of The British Allergy Foundation (continued)

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Capability of the audit in detecting irregularities, including fraud

Based on our understanding of the charity and the sector as a whole, and through discussion with the Trustees and other management (as required by auditing standards), we identified that the principal risks of non-compliance with laws and regulations related to health and safety and employment law. We considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as the Charities SORP (FRS 102) Second Edition (released October 2019), the Companies Act 2006, taxation and pension legislation. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit. We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to incorrect recognition of legacy income, posting inappropriate journal entries and management bias in accounting estimates and judgemental areas of the financial statements. Audit procedures performed by the engagement team included:

- Discussions with management and assessment of known or suspected instances of non-compliance with laws and regulations (including health and safety) and fraud; and
- Assessment of identified fraud risk factors; and
- Review of expenditure to confirm no evidence of personal benefit; and
- Identifying and assessing the design effectiveness of controls that management has in place to prevent and detect fraud; and
- Challenging assumptions and judgements made by management in its significant accounting estimates; and
- Performing analytical procedures to identify any unusual or unexpected relationships, including related party transactions, that may indicate risks of material misstatement due to fraud; and
- Confirmation of related parties with management, and review of transactions throughout the period to identify any previously undisclosed transactions with related parties outside the normal course of business; and
- Reading minutes of meetings of those charged with governance; and
- Review of significant and unusual transactions and evaluation of the underlying financial rationale supporting the transactions; and
- Identifying and testing journal entries, in particular any manual entries made at the year end for financial statement preparation.

Independent auditors' report to the Members of The British Allergy Foundation (continued)

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

As part of an audit in accordance with ISAs (UK), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion of the effectiveness of the charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Trustees.
- Conclude on the appropriateness of the Trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditors' report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the Group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

The British Allergy Foundation
(A company limited by guarantee)

Independent auditors' report to the Members of The British Allergy Foundation (continued)

Use of our report

This report is made solely to the charitable company's trustees, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, Part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.

Kreston Reeves LLP

Samantha Rouse FCCA DChA (Senior statutory auditor)

for and on behalf of
Kreston Reeves LLP

Chartered Accountants
Statutory Auditor

Canterbury

Date: 22 November 2024

Kreston Reeves LLP are eligible to act as auditors in terms of section 1212 of the Companies Act 2006.

The British Allergy Foundation
(A company limited by guarantee)

Consolidated Statement of financial activities (incorporating income and expenditure account)
For the year ended 31 March 2024

	Note	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Income from:					
Donations and legacies	3	51,843	51,643	103,486	158,523
Charitable activities	4	27,764	-	27,764	22,410
Other trading activities	5	1,136,222	-	1,136,222	1,338,224
Investments	6	19,143	-	19,143	5,691
Other income	7	113,688	-	113,688	-
Total income		1,348,660	51,643	1,400,303	1,524,848
Expenditure on:					
Raising funds	8	206,523	-	206,523	286,972
Charitable activities	9	1,102,991	95,183	1,198,174	1,386,245
Total expenditure		1,309,514	95,183	1,404,697	1,673,217
Net movement in funds		39,146	(43,540)	(4,394)	(148,369)
Reconciliation of funds:					
Total funds brought forward		861,273	106,057	967,330	1,115,699
Net movement in funds		39,146	(43,540)	(4,394)	(148,369)
Total funds carried forward		900,419	62,517	962,936	967,330

The Consolidated statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 28 to 54 form part of these financial statements.

The British Allergy Foundation
(A company limited by guarantee)
Registered number: 04509293

Consolidated balance sheet
As at 31 March 2024

	Note	2024 £	2023 £
Fixed assets			
Intangible assets	14	61,947	92,521
Tangible assets	15	17,260	17,227
Investments	16	14	14
		<u>79,221</u>	<u>109,762</u>
Current assets			
Stocks	17	2,252	961
Debtors	18	299,567	294,920
Investments	19	200,000	462,249
Cash at bank and in hand		667,900	520,896
		<u>1,169,719</u>	<u>1,279,026</u>
Creditors: amounts falling due within one year	20	(286,004)	(421,458)
Net current assets		<u>883,715</u>	<u>857,568</u>
Total net assets		<u><u>962,936</u></u>	<u><u>967,330</u></u>
Charity funds			
Restricted funds	21	62,517	106,057
Unrestricted funds	21	900,419	861,273
Total funds		<u><u>962,936</u></u>	<u><u>967,330</u></u>

The British Allergy Foundation
(A company limited by guarantee)
Registered number: 04509293

Consolidated balance sheet (continued)
As at 31 March 2024

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



Mr P Frampton
Chair

Date: 21/11/2024

The notes on pages 28 to 54 form part of these financial statements.

The British Allergy Foundation
(A company limited by guarantee)
Registered number: 04509293

Charity balance sheet
As at 31 March 2024

	Note	2024 £	2023 £
Fixed assets			
Intangible assets	14	61,947	92,521
Tangible assets	15	17,118	17,037
Investments	16	16	16
		<u>79,081</u>	<u>109,574</u>
Current assets			
Stocks	17	2,252	961
Debtors	18	79,976	206,701
Investments	19	200,000	462,249
Cash at bank and in hand		638,521	260,287
		<u>920,749</u>	<u>930,198</u>
Creditors: amounts falling due within one year	20	(58,075)	(93,623)
Net current assets		<u>862,674</u>	<u>836,575</u>
Total net assets		<u><u>941,755</u></u>	<u><u>946,149</u></u>
Charity funds			
Restricted funds	21	62,517	106,057
Unrestricted funds	21	879,238	840,092
Total funds		<u><u>941,755</u></u>	<u><u>946,149</u></u>

The Charity's net movement in funds for the year was £6,969 (2023 - £(128,681)).

The British Allergy Foundation
(A company limited by guarantee)
Registered number: 04509293

Charity balance sheet (continued)
As at 31 March 2024

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



Mr P Frampton

Chair

Date: 21/11/2024

The notes on pages 28 to 54 form part of these financial statements.

The British Allergy Foundation
(A company limited by guarantee)

Consolidated statement of cash flows
For the year ended 31 March 2024

	Note	2024 £	2023 £
Cash flows from operating activities			
Net cash (used in)/provided by operating activities	24	(115,024)	(327,071)
Cash flows from investing activities			
Interest received		19,143	5,691
Purchase of intangible assets		(2,700)	(550)
Purchase of tangible fixed assets		(16,664)	(1,201)
Decrease/(increase) in short term deposit accounts		262,249	(2,249)
Net cash provided by investing activities		262,028	1,691
Change in cash and cash equivalents in the year		147,004	(325,380)
Cash and cash equivalents at the beginning of the year		520,896	846,276
Cash and cash equivalents at the end of the year	25	667,900	520,896

The notes on pages 28 to 54 form part of these financial statements

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

1. General information

The British Allergy Foundation is a charitable private company limited by guarantee, incorporated in England, Wales and Scotland. The liability of each member in the event of a winding up is limited to £1. The registered office is London House Business Centre, Thames Road, Crayford, Dartford, England, DA1 4SL.

The principal activity of the Charity is to increase awareness of allergy and causes of anaphylaxis through services, advocacy, campaigns for policy and legislation changes, education on management and prevention of allergy, supporting the allergic community, promoting research into causes of allergy and improving quality of life, advocacy, advice, support and information services.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The British Allergy Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Consolidated statement of financial activities (SOFA) and Consolidated balance sheet consolidate the financial statements of the Charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

The Charity has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of financial activities in these financial statements.

Notes to the financial statements
For the year ended 31 March 2024

2. Accounting policies (continued)

2.2 Income

All income is recognised once the Charity has entitlement to the income, after any performance conditions have been met, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Incoming resources from charitable trading activities are recognised as follows:

The sale of goods - revenue is recognised when donated goods are sold;

The rendering of services - revenue is recognised as follows:

Applications for the seal of approval when the application has been signed and the terms agreed;

Renewal of the seal of approval in the month of commencement of the new period; and

Services, such as training, in the month the services are supplied.

Voluntary income is received by way of grants, donations, legacies and gifts and is included in full in the Statement of Financial Activities when receivable. Grants, where entitlement is not conditional on the delivery of a specific performance by the charity, are recognised when the charity becomes unconditionally entitled to the grant.

Incoming resources from grants, where related to performance and specific deliverables, are accounted for as the charity earns the right to consideration by its performance.

Investment income is included when receivable.

Legacies are included when the Charity has legal entitlement, the amount can be measured reliably and it is probable that the income will be received.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

2.3 Expenditure

Resources expended are included in the Statement of Financial Activities on an accrual basis and have been classified under headings that aggregate all costs related to the category inclusive of any VAT which cannot be recovered. Expenditure is recognised where there is a legal or constructive obligation to make payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Fundraising costs are those incurred in seeking voluntary contributions and the staging of fundraising events.

Support costs

Support costs are those costs incurred directly in support of expenditure on the objects of the company.

Allocation to support costs

Certain expenditure is directly attributable to specific activities and has been included in those cost categories. Certain other costs, which are attributable to more than one activity, are apportioned across cost categories on the basis of an estimate of the proportion of time spent by staff on those activities.

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

2. Accounting policies (continued)

2.4 Government grants

Income from government grants is included at the point of application for the funds if that funding is considered to meet the criteria of measurability, reliability and probability. Otherwise it is accounted for upon receipt.

2.5 Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the reporting date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Consolidated statement of financial activities.

2.6 Intangible assets and amortisation

Intangible assets costing £1,000 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on a straight-line basis over its expected useful life.

Amortisation is provided on the following bases:

Website	- 10 % straight line
CRM Development costs	- 10 % straight line

2.7 Tangible fixed assets and depreciation

Tangible fixed assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, on a reducing balance basis. All new fixed assets purchased in 2022/23 and subsequently are depreciated on a straight-line basis.

Depreciation is provided on the following basis:

Furniture and fittings	- 25% reducing balance
Computer & office equipment	- 25% reducing balance

Notes to the financial statements
For the year ended 31 March 2024

2. Accounting policies (continued)

2.8 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Consolidated statement of financial activities.

Investments in subsidiaries are valued at cost less provision for impairment.

2.9 Stocks

Stocks are valued at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

2.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Consolidated statement of financial activities as a finance cost.

2.13 Financial instruments

The Group only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

2. Accounting policies (continued)

2.14 Operating leases

Rentals paid under operating leases are charged to the Consolidated Statement of Financial Activities on a straight-line basis over the lease term.

2.15 Pensions

The Group operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Group to the fund in respect of the year.

2.16 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Group for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Income from donations and legacies

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £
Donations	48,286	-	48,286
Legacies	53	-	53
Grants	3,504	51,643	55,147
	<u>51,843</u>	<u>51,643</u>	<u>103,486</u>
	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £
Donations	36,265	-	36,265
Grants	-	122,258	122,258
	<u>36,265</u>	<u>122,258</u>	<u>158,523</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

4. Income from charitable activities

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Sale of translation cards	26,430	26,430	22,005
Fees received	1,334	1,334	405
	<u>27,764</u>	<u>27,764</u>	<u>22,410</u>

5. Income from other trading activities

Income from fundraising events

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Fundraising events	<u>13,550</u>	<u>13,550</u>	<u>20,918</u>

Income from trading subsidiary

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Seal of approval	220,453	220,453	357,815
Renewals	675,103	675,103	689,894
Allergy Friendly Products	85,333	85,333	60,700
Corporate partners	137,383	137,383	205,000
Alerts	4,400	4,400	3,120
Allergy Awareness Scheme	-	-	777
	<u>1,122,672</u>	<u>1,122,672</u>	<u>1,317,306</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

6. Investment income

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Interest received	19,143	19,143	5,691

7. Other incoming resources

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Other income	113,688	113,688	-

8. Expenditure on raising funds

Costs of raising voluntary income

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Direct costs	4,733	4,733	2,178
Professional fees	4,722	4,722	2,653
	9,455	9,455	4,831

Fundraising trading expenses

	Unrestricted funds 2024 £	Total funds 2024 £
Fundraising expenses	16,558	16,558

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

8. Expenditure on raising funds (continued)

Fundraising trading expenses (continued)

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £
Fundraising expenses	9,132	31,290	40,422

Expenditure on trading subsidiary

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Cost of sales	180,510	180,510	241,719

9. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
Charitable activities	1,102,991	95,183	1,198,174

	Unrestricted funds 2023 £	Total 2023 £
Charitable activities	1,386,245	1,386,245

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

10. Analysis of expenditure by activities

	Activities undertaken directly 2024 £	Support costs 2024 £	Total funds 2024 £
Charitable activities	942,299	255,875	1,198,174

	Activities undertaken directly 2023 £	Support costs 2023 £	Total funds 2023 £
Charitable activities	1,024,622	361,623	1,386,245

Analysis of direct costs

	Total funds 2024 £	Total funds 2023 £
Staff costs	830,146	877,828
Communications	91,208	127,360
Other direct costs	20,945	19,434
	942,299	1,024,622

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

10. Analysis of expenditure by activities (continued)

Analysis of support costs

	Total funds 2024 £	Total funds 2023 £
Premises	90,589	117,758
Communications	284	5,292
Legal & professional	5,770	32,889
General office expenses	94,103	111,753
Depreciation, amortisation & impairment	38,541	27,450
Financial charges	9,238	31,506
Governance costs	17,350	34,975
	255,875	361,623

11. Auditors' remuneration

The auditors' remuneration amounts to an auditor fee of £13,700 (2023 - £10,350), and remuneration in relation to the preparation of the financial statements and corporation tax returns of £3,545 (2023 - £4,125).

12. Staff costs

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Wages and salaries	740,962	783,375	740,962	783,375
Social security costs	69,231	74,217	69,231	74,217
Contribution to defined contribution pension schemes	19,953	20,236	19,953	20,236
	830,146	877,828	830,146	877,828

The average number of persons employed by the Charity during the year was as follows:

	Group 2024 No.	Group 2023 No.	Charity 2024 No.	Charity 2023 No.
Headcount	23	22	23	22

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

12. Staff costs (continued)

The average headcount expressed as full-time equivalents was:

	Group 2024 No.	Group 2023 No.	Charity 2024 No.	Charity 2023 No.
Charitable activities	19	19	19	19
Generating funds	3	3	3	3
	<u>22</u>	<u>22</u>	<u>22</u>	<u>22</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	Group 2024 No.	Group 2023 No.
In the band £60,001 - £70,000	-	2
In the band £70,001 - £80,000	1	-

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

13. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2023 - £NIL).

During the year ended 31 March 2024, expenses totalling £4,690 were reimbursed or paid directly to 6 Trustees (2023 - £2,823 to 5 Trustees). These related to travel and hotel costs to attend Board meetings.

14. Intangible assets

Group

	Patents £	Computer software £	Total £
Cost			
At 1 April 2023	74,931	144,644	219,575
Additions	2,700	-	2,700
At 31 March 2024	77,631	144,644	222,275
Amortisation			
At 1 April 2023	51,210	75,844	127,054
Charge for the year	3,810	14,464	18,274
Impairment charge	15,000	-	15,000
At 31 March 2024	70,020	90,308	160,328
Net book value			
At 31 March 2024	7,611	54,336	61,947
At 31 March 2023	23,721	68,800	92,521

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

14. Intangible assets (continued)

Charity

	Patents £	Computer software £	Total £
Cost			
At 1 April 2023	74,931	144,644	219,575
Additions	2,700	-	2,700
At 31 March 2024	77,631	144,644	222,275
Amortisation			
At 1 April 2023	51,210	75,844	127,054
Charge for the year	3,810	14,464	18,274
Impairment charge	15,000	-	15,000
At 31 March 2024	70,020	90,308	160,328
Net book value			
At 31 March 2024	7,611	54,336	61,947
At 31 March 2023	23,721	68,800	92,521

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

15. Tangible fixed assets

Group

	Furniture & fittings £	Computer & office equipment £	Total £
Cost or valuation			
At 1 April 2023	14,455	53,571	68,026
Additions	13,926	2,738	16,664
Disposals	(13,762)	(17,583)	(31,345)
At 31 March 2024	14,619	38,726	53,345
Depreciation			
At 1 April 2023	6,834	43,965	50,799
Charge for the year	2,352	2,915	5,267
On disposals	(6,708)	(13,273)	(19,981)
At 31 March 2024	2,478	33,607	36,085
Net book value			
At 31 March 2024	12,141	5,119	17,260
At 31 March 2023	7,621	9,606	17,227

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

15. Tangible fixed assets (continued)

Charity

	Furniture & fittings £	Computer & office equipment £	Total £
Cost or valuation			
At 1 April 2023	14,455	50,908	65,363
Additions	13,926	2,738	16,664
Disposals	(13,762)	(17,583)	(31,345)
At 31 March 2024	14,619	36,063	50,682
Depreciation			
At 1 April 2023	6,834	41,492	48,326
Charge for the year	2,352	2,867	5,219
On disposals	(6,708)	(13,273)	(19,981)
At 31 March 2024	2,478	31,086	33,564
Net book value			
At 31 March 2024	12,141	4,977	17,118
At 31 March 2023	7,621	9,416	17,037

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

16. Fixed asset investments

	Investments in subsidiary companies £
Group	
Cost or valuation	
At 1 April 2023	14
At 31 March 2024	<u>14</u>
Charity	
Cost or valuation	
At 1 April 2023	16
At 31 March 2024	<u>16</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

16. Fixed asset investments (continued)

Principal subsidiaries

The following were subsidiary undertakings of the Charity:

Names	Company number	Registered office or principal place of business	Class of shares	Holding	Included in consolidation
Allergy Research Ltd	03550847	London House Business Centre, Thames Road, Crayford, Dartford, England, DA1 4SL	Ordinary	100%	Yes
Allergy UK Ltd (Dormant)	06302734	London House Business Centre, Thames Road, Crayford, Dartford, England, DA1 4SL	Ordinary	100%	Yes
Allergy Aware Scheme Ltd (Dormant)	06300759	London House Business Centre, Thames Road, Crayford, Dartford, England, DA1 4SL	Ordinary	100%	Yes
Allergy England Ltd (Dormant)	08494679	London House Business Centre, Thames Road, Crayford, Dartford, England, DA1 4SL	Ordinary	100%	Yes
Allergy Scotland Ltd (Dormant)	SC447980	272 Bath Street, Glasgow, G2 4JR	Ordinary	100%	No
Allergy Europe Ltd (Dormant)	08695950	London House Business Centre, Thames Road, Crayford, Dartford, England, DA1 4SL	Ordinary	100%	Yes
Allergy Northern Ireland Ltd (Dormant)	NI679729	58, Antrim Enterprise Agency, Unit 19 Greystone Road, Antrim, County Antrim, Northern Ireland, BT41 1JZ	Ordinary	100%	No
Allergy Wales Ltd (Dormant)	13459606	International House, 10 Churchill Way, Cardiff, United Kingdom, CF10 2HE	Ordinary	100%	No

The financial results of the subsidiaries for the year were:

Names	Income £	Expenditure £	Net assets £
Allergy Research Ltd	1,123,773	(1,123,773)	21,183
Allergy UK Ltd (Dormant)	-	-	2
Allergy Aware Scheme Ltd (Dormant)	-	-	2
Allergy England Ltd (Dormant)	-	-	2
Allergy Scotland Ltd (Dormant)	-	-	2
Allergy Europe Ltd (Dormant)	-	-	2
Allergy Northern Ireland Ltd (Dormant)	-	-	2
Allergy Wales Ltd (Dormant)	-	-	2

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

17. Stocks

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Goods for resale	2,252	961	2,252	961

18. Debtors

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Due within one year				
Trade debtors	257,371	214,822	350	-
Amounts owed by group undertakings	-	-	37,430	133,092
Other debtors	5,580	14,951	5,580	8,462
Prepayments and accrued income	36,616	65,147	36,616	65,147
	299,567	294,920	79,976	206,701

19. Current asset investments

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Short term deposits	200,000	462,249	200,000	462,249

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

20. Creditors: Amounts falling due within one year

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Trade creditors	30,409	78,215	10,353	44,615
Other taxation and social security	23,152	19,016	21,387	19,016
Other creditors	1,677	1,988	1,677	1,988
Accruals and deferred income	230,766	322,239	24,658	28,004
	286,004	421,458	58,075	93,623
	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Deferred income at 1 April 2023	194,024	92,964	12,500	18,024
Resources deferred during the year	124,317	194,024	12,500	12,500
Amounts released from previous periods	(194,024)	(92,964)	(12,500)	(18,024)
Deferred income at 31 March 2024	124,317	194,024	12,500	12,500

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

21. Statement of funds

Statement of funds - current year

	Balance at 1 April 2023 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2024 £
Unrestricted funds					
Designated funds					
Fixed Asset Fund	17,037	-	(5,219)	5,300	17,118
Contingency Fund	466,220	-	-	-	466,220
Public Affairs Campaign Reserve	16,395	-	-	-	16,395
Digital Media Reserve	6,455	-	-	-	6,455
	<u>506,107</u>	<u>-</u>	<u>(5,219)</u>	<u>5,300</u>	<u>506,188</u>
	Balance at 1 April 2023 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2024 £
General funds					
General Free Reserve	333,985	1,348,660	(1,304,295)	(5,300)	373,050
Allergy Research Limited	21,181	-	-	-	21,181
	<u>355,166</u>	<u>1,348,660</u>	<u>(1,304,295)</u>	<u>(5,300)</u>	<u>394,231</u>
Total Unrestricted funds	<u>861,273</u>	<u>1,348,660</u>	<u>(1,309,514)</u>	<u>-</u>	<u>900,419</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

21. Statement of funds (continued)

	Balance at 1 April 2023 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2024 £
Restricted funds					
HCP Scotland Training Fund	420	-	(420)	-	-
Novartis	1,408	-	-	-	1,408
Sanofi Youth	77,583	-	(77,583)	-	-
Nutricia	4,680	24,186	(4,680)	-	24,186
Pfizer	9,466	-	-	-	9,466
Garfield Weston	12,500	25,000	(12,500)	-	25,000
IADPO	-	2,457	-	-	2,457
	<u>106,057</u>	<u>51,643</u>	<u>(95,183)</u>	<u>-</u>	<u>62,517</u>
Total of funds	<u>967,330</u>	<u>1,400,303</u>	<u>(1,404,697)</u>	<u>-</u>	<u>962,936</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

21. Statement of funds (continued)

Statement of funds - prior year

	Balance at 1 April 2022 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2023 £
Unrestricted funds					
Designated funds					
Awareness Campaign Reserve	5,120	-	(5,120)	-	-
Resource Building Reserve	100,291	-	(100,291)	-	-
IT Reserve	10,000	-	(10,000)	-	-
Fundraising Reserve	42,562	-	(42,562)	-	-
Fixed Asset Fund	26,720	-	(6,830)	(2,853)	17,037
Contingency Fund	466,220	-	-	-	466,220
Project Delivery Reserve	75,000	-	(75,000)	-	-
Public Affairs Campaign Reserve	16,395	-	-	-	16,395
Digital Media Reserve	14,795	-	(8,340)	-	6,455
	<u>757,103</u>	<u>-</u>	<u>(248,143)</u>	<u>(2,853)</u>	<u>506,107</u>
	Balance at 1 April 2022 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2023 £
General funds					
General Free Reserve	322,326	1,402,590	(1,393,784)	2,853	333,985
Allergy Research Limited	21,181	-	-	-	21,181
	<u>343,507</u>	<u>1,402,590</u>	<u>(1,393,784)</u>	<u>2,853</u>	<u>355,166</u>
Total Unrestricted funds	<u>1,100,610</u>	<u>1,402,590</u>	<u>(1,641,927)</u>	<u>-</u>	<u>861,273</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

21. Statement of funds (continued)

	Balance at 1 April 2022 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2023 £
Restricted funds					
HCP Scotland Training Fund	420	-	-	-	420
Novartis	1,408	-	-	-	1,408
Global Skin	13,261	-	(13,261)	-	-
Sanofi Youth	-	77,583	-	-	77,583
Nutricia	-	4,680	-	-	4,680
Pfizer	-	9,466	-	-	9,466
Aimmune	-	5,529	(5,529)	-	-
Garfield Weston	-	25,000	(12,500)	-	12,500
	<u>15,089</u>	<u>122,258</u>	<u>(31,290)</u>	<u>-</u>	<u>106,057</u>
Total of funds	<u>1,115,699</u>	<u>1,524,848</u>	<u>(1,673,217)</u>	<u>-</u>	<u>967,330</u>

The HCP (health care professional) Scotland Training Fund is to enable the charity to encourage training in allergy, by making grants to committed HCPs to meet a percentage of their training costs, at a time when the Health Service has reduced their funding in this area.

Novartis provided grant funding to create resources for people living with CSU in an e-booklet and a video. The resources aimed to provide an understandable information to help them with their engagement with a GP.

Global Skin provided grant funding for a Masterclass for healthcare professionals to manage skin allergy.

Sanofi Youth is in relation to the Development of Youth Engagement with Allergy.

Nutricia provided sponsorship funding for the dietitian service that offer dietetic support for the under 5 year olds.

Garfield Weston is to help fund the operation of the Allergy helpline.

Pfizer fund is for producing a booklet on skin to skin, leaflet on Atopic Eczema and a leaflet on Eczema blood monitoring.

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

22. Summary of funds

Summary of funds - current year

	Balance at 1 April 2023 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2024 £
Designated funds	506,107	-	(5,219)	5,300	506,188
General funds	355,166	1,348,660	(1,304,295)	(5,300)	394,231
Restricted funds	106,057	51,643	(95,183)	-	62,517
	<u>967,330</u>	<u>1,400,303</u>	<u>(1,404,697)</u>	<u>-</u>	<u>962,936</u>

Summary of funds - prior year

	Balance at 1 April 2022 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2023 £
Designated funds	757,103	-	(248,143)	(2,853)	506,107
General funds	343,507	1,402,590	(1,393,784)	2,853	355,166
Restricted funds	15,089	122,258	(31,290)	-	106,057
	<u>1,115,699</u>	<u>1,524,848</u>	<u>(1,673,217)</u>	<u>-</u>	<u>967,330</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

23. Analysis of net assets between funds

Analysis of net assets between funds - current period

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £
Tangible fixed assets	17,260	-	17,260
Intangible fixed assets	61,947	-	61,947
Fixed asset investments	14	-	14
Current assets	1,107,203	62,517	1,169,720
Creditors due within one year	(286,005)	-	(286,005)
Total	900,419	62,517	962,936

Analysis of net assets between funds - prior period

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £
Tangible fixed assets	17,227	-	17,227
Intangible fixed assets	92,521	-	92,521
Fixed asset investments	14	-	14
Current assets	1,172,969	106,057	1,279,026
Creditors due within one year	(421,458)	-	(421,458)
Total	861,273	106,057	967,330

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

24. Reconciliation of net movement in funds to net cash flow from operating activities

	Group 2024 £	Group 2023 £
Net expenditure for the period (as per Statement of Financial Activities)	(4,394)	(148,369)
Adjustments for:		
Depreciation charges	5,267	6,989
Amortisation charges	18,274	21,039
Interest received	(19,143)	(5,691)
Profit on disposal of intangibles	-	17,507
(Profit)/ loss on disposal of fixed assets	11,363	4,416
Increase in stocks	(1,291)	(200)
Decrease/(increase) in debtors	(54,937)	93,334
Decrease in creditors	(85,163)	(316,096)
Impairment charges	15,000	-
Net cash used in operating activities	(115,024)	(327,071)

25. Analysis of cash and cash equivalents

	Group 2024 £	Group 2023 £
Cash in hand	667,900	520,896
Total cash and cash equivalents	667,900	520,896

26. Analysis of changes in net debt

	At 1 April 2023 £	Cash flows £	At 31 March 2024 £
Cash at bank and in hand	520,896	147,004	667,900
Liquid investments	462,249	(262,249)	200,000
	983,145	(115,245)	867,900

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2024

27. Pension commitments

The Group operates a defined contribution pension scheme for its employees. The pension cost charge for the period represents contributions payable by the Charity to the scheme and amounted to £19,953 (2023 - £20,236). At the balance sheet date £Nil was recognised as a liability owed to the scheme (2023 - £Nil).

28. Operating lease commitments

At 31 March 2024 the Group and the Charity had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Not later than 1 year	69,485	92,427	69,485	92,427
Later than 1 year and not later than 5 years	219,544	17,824	219,544	17,824
	289,029	110,251	289,029	110,251

29. Related party transactions

The charity has not entered into any related party transaction during the year (2023: £Nil), nor are there any outstanding balances owing between related parties and the Charity at 31 March 2024 (2023: £Nil).

30. Controlling party

There is no ultimate controlling party.